Matinas BioPharma (MTNB) Misses Q3 EPS by 1c; Reports Cash and Cash Equivalents of $53.8M

Matinas BioPharma (NYSE: MTNB) reported Q3 EPS of ($0.03), $0.01 worse than the analyst estimate of ($0.02).

For earnings history and earnings-related data on Matinas BioPharma (MTNB) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• Boost Run posts Q2 revenue of $31.1M, up 270% year over year